A non-invasive Alzheimer’s therapy is moving closer to patients, and it could reshape how brain health is treated.
In this episode, Christian Howell, CEO of Cognito Therapeutics, joins Saul live at DeviceTalks Boston to discuss how the company is advancing a novel Alzheimer’s therapy that uses sensory stimulation through light, sound, and touch. He shares insights from Cognito’s HOPE study, the largest non-pharmacologic clinical trial in neurodegenerative disease, involving 673 participants across 70 sites. Christian explains why a strong evidence strategy is essential not only for regulatory approval but also for reimbursement, clinical adoption, and patient access. He also reflects on leadership lessons centered on service, humility, humor, and the importance of aligning stakeholders across the healthcare ecosystem to improve Alzheimer’s care.
Tune in to hear how Christian Howell and Cognito Therapeutics are working to bring new hope, stronger evidence, and a more accessible path forward for Alzheimer’s patients and families!
Resources: